Coexpression of soluble and membrane-bound avian influenza virus H5 by recombinant Newcastle disease virus leads to an increase in antigen levels.
Animals
Antibodies, Viral
/ immunology
Antigens, Viral
/ immunology
Cell Line
Chickens
Cricetinae
Hemagglutinin Glycoproteins, Influenza Virus
/ immunology
Influenza A Virus, H5N1 Subtype
/ immunology
Influenza Vaccines
/ immunology
Influenza in Birds
/ immunology
Newcastle Disease
/ immunology
Newcastle disease virus
/ immunology
Virus Shedding
/ immunology
Newcastle disease virus
avian influenza
expression level
recombinant
soluble antigene
Journal
The Journal of general virology
ISSN: 1465-2099
Titre abrégé: J Gen Virol
Pays: England
ID NLM: 0077340
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
27
3
2020
medline:
27
10
2020
entrez:
27
3
2020
Statut:
ppublish
Résumé
Newcastle disease virus (NDV) vectors expressing avian influenza virus (AIV) haemagglutinin (HA) of subtype H5 simultaneously protect chickens from Newcastle disease (ND) as well as avian influenza (AI). The expressed, membrane-bound surface protein HA is incorporated into virions while soluble HA has been described as a potent antigen. We tested whether co-expression of both HA variants from the same NDV vector increased the overall level of HA, which could be important for optimal immunogenicity. Recombinant NDVsolH5_H5 co-expressed membrane-bound H5 of highly pathogenic (HP) AIV H5N1, detectable in infected cells, and soluble H5, which was secreted into the supernatant. This virus was compared to recombinant NDV that express either membrane-bound (rNDVH5) or soluble H5 (rNDVsolH5). Replication in embryonated chicken eggs (ECEs) and in cell culture, as well as pathogenicity in ECEs, was not influenced by the second heterologous transcriptional unit. However, the co-expression of soluble H5 with membrane-bound H5 increased total protein level about 5.25-fold as detected by MS quantification. Hence, this virus is very interesting as a vaccine virus in chickens against HPAIV infections in situations in which previous H5-expressing NDVs have reached their limit, such as in the face of pre-existing AIV maternal immunity.
Identifiants
pubmed: 32209169
doi: 10.1099/jgv.0.001405
doi:
Substances chimiques
Antibodies, Viral
0
Antigens, Viral
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM